BTIG Remains Neutral on Juno Therapeutics (JUNO); Says JCAR015 Will Have 'Limited Impact' on Ests

November 23, 2016 12:15 PM EST
Get Alerts JUNO Hot Sheet
Price: $20.43 +2.66%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade JUNO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BTIG affirms Juno Therapeutics Inc. (Nasdaq: JUNO) at Neutral after the company announced that the ROCKET Study had been voluntarily placed on hold amid two recent, cerebral edema-related deaths.

The firm commented today, This follows the FDA mandated clinical hold back in July after several patients died in the ROCKET study, but the trial hold was lifted after a week with a protocol change to eliminate fludarabine preconditioning. Expectations for JCAR015 were reduced after the first clinical hold, so although today’s announcement will be a negative for sentiment on JUNO heading into ASH, it has limited impact on our financial estimates.

We think that the JCAR015 program will be terminated, with the ROCKET study for Adult ALL being the lead study. Management is still evaluating strategic options, and may see a path forward but would not commit to a decision on the call with investors.

For an analyst ratings summary and ratings history on Juno Therapeutics click here. For more ratings news on Juno Therapeutics click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

BTIG

Add Your Comment